AstraZeneca

AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
  • TickerAZN
  • ISINGB0009895292
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom
Team Pharma

ODDO : US elections: a cautious stance is in order on European big pharma

The US elections on 3 November are nearly upon us, and with them the usual package of measures relating to the health sector. The main measures to have been made public at this stage are clearly deflationary. In an uncertain climate for the industry, we have made several rating changes, with two upgrades, on AstraZeneca (Buy vs Reduce), and GSK (Buy vs Neutral), and two downgrades, on Roche (Reduce vs Buy), and Novartis (Neutral vs Buy). We are still at Buy on Sanofi and Neutral ...

Team Pharma

ODDO : Elections US: prudence sur la Big Pharma européenne

L’élection américaine du 3 novembre approche et avec elle son traditionnel lot de mesures relatives au secteur de la santé. Les principales mesures rendues publiques, à ce stade, sont clairement déflationnistes. Dans ce contexte d'incertitudes pour le secteur, nous opérons plusieurs changements d’opinions avec deux relèvements, AstraZeneca (Achat vs Alléger), GSK (Achat vs Neutre), et deux révisions en baisse, Roche (Alléger vs Achat), Novartis (Neutre vs Achat). Nous restons à l...

Team Pharma

ODDO : US elections: a cautious stance is in order on European big pharma

The US elections on 3 November are nearly upon us, and with them the usual package of measures relating to the health sector. The main measures to have been made public at this stage are clearly deflationary. In an uncertain climate for the industry, we have made several rating changes, with two upgrades, on AstraZeneca (Buy vs Reduce), and GSK (Buy vs Neutral), and two downgrades, on Roche (Reduce vs Buy), and Novartis (Neutral vs Buy). We are still at Buy on Sanofi and Neutral ...

Dominic Rose ...
  • Naresh Chouhan

Big Pharma Margins to Benefit From COVID (Thematic research, 12 pgs)

We highlight numerous doc surveys showing they are unlikely to go back to pre-COVID levels of interaction with Big Pharma sales forces & are now much more amenable to digital marketing. Lower S&M spend should drive higher margins despite some of the savings being reinvested. We estimate the savings could be 3-4% of 2019 EBIT yet consensus hasn’t increased its 2021 EBIT margin forecasts for most in the industry. We expect this to be a multi-year structural benefit as new technology is adopted by Pharma & its customers. We show Novo could be the largest beneficiary, Roche the least. For access ...

ASTRAZENECA sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of ASTRAZENECA (GB), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date September 18, 2020, the closing price was GBp 8,746.00 and its potential was estimated at GBp 9,707.29.

Dave Nicoski ...
  • Ross LaDuke

Global Equity Strategy

Global equities (MSCI ACWI) are testing 52-week lows as prices have been consolidating over the last 1-2 months. Investors' primary sources of angst continue to revolve around concerns of (1) the global shift toward tighter monetary policy and the potential for perceived policy missteps, (2) trade and tariffs, and (3) the potential negative effects both (1) and (2) may have on global growth. Comments from Fed Chair Powell that interest rates are “just below” the neutral rate and the 90-day tariff ceasefire agreement between the U.S. and China have not been able to calm the markets. In Euro...

Jérôme VINERIER

Analyse court terme - ASTRAZENECA : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 6 145,00 p et 6 502,00 p. La tendance serait invalidée sous le support à 5 100,00 p.

Jérôme VINERIER

Short term view - ASTRAZENECA : The background trend is clearly bullish.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at 6,145.00 p and 6,502.00 p. The trend would be invalidated below the support at 5,100.00 p.

Jérôme VINERIER

Analyse court terme - ASTRAZENECA : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 6 145,00 p. La rupture du support à 5 100,00 p invaliderait cette tendance.

Jérôme VINERIER

Short term view - ASTRAZENECA : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 6,145.00 p. Breaking below the support at 5,100.00 p would invalidate the trend.

Eric Le Berrigaud

ASTRAZENECA - BUY - Top Picks | 8780p(+1%) ADAURA: outstanding results, paving the way for new SoC in adjuvant NSCLC

Top-line data even greater then thought Modelling consequences

Team Pharma

ODDO : US elections: a cautious stance is in order on European big pharma

The US elections on 3 November are nearly upon us, and with them the usual package of measures relating to the health sector. The main measures to have been made public at this stage are clearly deflationary. In an uncertain climate for the industry, we have made several rating changes, with two upgrades, on AstraZeneca (Buy vs Reduce), and GSK (Buy vs Neutral), and two downgrades, on Roche (Reduce vs Buy), and Novartis (Neutral vs Buy). We are still at Buy on Sanofi and Neutral ...

Team Pharma

ODDO : Elections US: prudence sur la Big Pharma européenne

L’élection américaine du 3 novembre approche et avec elle son traditionnel lot de mesures relatives au secteur de la santé. Les principales mesures rendues publiques, à ce stade, sont clairement déflationnistes. Dans ce contexte d'incertitudes pour le secteur, nous opérons plusieurs changements d’opinions avec deux relèvements, AstraZeneca (Achat vs Alléger), GSK (Achat vs Neutre), et deux révisions en baisse, Roche (Alléger vs Achat), Novartis (Neutre vs Achat). Nous restons à l...

Team Pharma

ODDO : US elections: a cautious stance is in order on European big pharma

The US elections on 3 November are nearly upon us, and with them the usual package of measures relating to the health sector. The main measures to have been made public at this stage are clearly deflationary. In an uncertain climate for the industry, we have made several rating changes, with two upgrades, on AstraZeneca (Buy vs Reduce), and GSK (Buy vs Neutral), and two downgrades, on Roche (Reduce vs Buy), and Novartis (Neutral vs Buy). We are still at Buy on Sanofi and Neutral ...

Dominic Rose ...
  • Naresh Chouhan

Big Pharma Margins to Benefit From COVID (Thematic research, 12 pgs)

We highlight numerous doc surveys showing they are unlikely to go back to pre-COVID levels of interaction with Big Pharma sales forces & are now much more amenable to digital marketing. Lower S&M spend should drive higher margins despite some of the savings being reinvested. We estimate the savings could be 3-4% of 2019 EBIT yet consensus hasn’t increased its 2021 EBIT margin forecasts for most in the industry. We expect this to be a multi-year structural benefit as new technology is adopted by Pharma & its customers. We show Novo could be the largest beneficiary, Roche the least. For access ...

Martial Descoutures ...
  • Oussema Denguir
  • Sebastien Malafosse

AstraZeneca : Phase III trial of COVID-19 vaccine halted following adverse effects

>Vaccine trial put on hold after a severe adverse effect - As reported by the medical news website STAT overnight, AstraZeneca has confirmed that phase III trials of its COVID-19 vaccine have been halted following a suspected serious adverse effect. According to the NY Times, it is a rare instance of inflammation of the spinal cord (transverse myelitis) in the UK. This type of inflammation may be caused by a viral infection; note that AZN's vaccine is based on a viral...

Moody's announces completion of a periodic review of ratings of AstraZeneca PLC

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of AstraZeneca PLC. Global Credit Research- 07 Aug 2020. London, 07 August 2020-- Moody's Investors Service has completed a periodic review of the ratings of AstraZeneca PLC and other ratings that are associated with the same analytical unit.

AstraZeneca PLC: Credit metrics improvement trajectory remains on track following new collaboration with Daiichi Sankyo

Our credit view of AstraZeneca's new collaboration with Daiichi Sankyo following which we continue to expect a strong improvement in credit metrics

AstraZeneca PLC - March 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

AstraZeneca PLC: Update to credit analysis - metrics remain weak but deleveraging trajectory is strong

Our credit view of AstraZeneca, reflecting expectations that strong operating leverage over the next 2-3 years will materially improve currently weak credit metrics.

AstraZeneca PLC - December 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Alain William ...
  • Anis Zgaya
  • Fatma Ayachi
  • Hana Jomni
  • Louis Boujard, CFA
  • Marc Lavaud
  • Martial Descoutures
  • Michael Foundoukidis
  • Olfa Taamallah
  • Oussema Denguir
  • Oussema Ettaieb
  • Philippe Ourpatian
  • Sebastien Malafosse
  • Syrine Kabboura
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/09/2020

...

Alain William ...
  • Anis Zgaya
  • Fatma Ayachi
  • Hana Jomni
  • Louis Boujard, CFA
  • Marc Lavaud
  • Martial Descoutures
  • Michael Foundoukidis
  • Olfa Taamallah
  • Oussema Denguir
  • Oussema Ettaieb
  • Philippe Ourpatian
  • Sebastien Malafosse
  • Syrine Kabboura
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 09/09/2020

...

Bruno Cavalier ...
  • Louis Boujard, CFA
  • Philippe Ourpatian
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 07/27/2020

After years of unrealised €/$ bullish forecasts the single currency is finally on an upward trajectory. This change of course reflects a radical shift in the perception of the political risk associated with the European Union. The starting point for the rise (17 May) corresponds, moreover to the Franco-German announcement of the stimulus plan project. The European agreement of 21 July to begin the implementation process argues in favour, in a context of an upturn in PMIs, in favour of...

ASTRAZENECA sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of ASTRAZENECA (GB), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date September 18, 2020, the closing price was GBp 8,746.00 and its potential was estimated at GBp 9,707.29.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

Expert Corporate Governance Service (ECGS)

AstraZeneca – AGM 29 April 2020

Items 2, 10-12: Dividend, capital increases without preemptive rights and share buyback   AstraZenecans distribution policy is unsustainable and item of serious concern. For many years in a row, the dividend has been covered neither by EPS nor by free cash flows. The debt has increased significantly. In 2019, AstraZeneca diluted shareholders by the non-preemptive placement of 3.5% of the capital at a 1.5% discount. The Companyns dividend amounts $3,592m compare to raised share proceeds of $3,525m. This cost at least $75m to the company and its shareholders. The discount totalled $53m and the...

Expert Corporate Governance Service (ECGS)

AstraZeneca - AGM 26 April 2019

Item 2: Declare a Dividend  The proposed dividend is the same as that of the previous fiscal year. It has remained unchanged at $2.80 per share since 2015.  The Board maintains a progressive dividend policy and has the intention to maintain or grow the dividend each year with the aim of striking a balance between the interest of the business, financial creditors and shareholders. However, in the current year the dividend is not covered by earnings or free cash flow.  In fact, free cash flow has not been able to cover the dividend for five years in a row.  We recommend shareholders oppose.  I...

Astrazeneca PLC – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch